Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 10/20 | 0.60 |
| ▸ | REN | P00797 | 4/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.47 |
| ▸ | ITGAV | P06756 | 1/20 | 0.47 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.47 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PEPD | P12955 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17285637 | 0.87 | ACE (0.51) | ACERENTHRBALOX12KMT2A | |
| SCHEMBL9728258 | 0.83 | ACE (0.53) | ACERENTHRBALOX12KMT2A | |
| SCHEMBL4728479 | 0.83 | THRB (0.49) | ACERENTHRBALOX12KMT2A | |
| SCHEMBL17285592 | 0.81 | ACE (0.48) | ACERENTHRBALOX12KMT2A | |
| SCHEMBL6405913 | 0.79 | FKBP1A (0.46) | ACEKMT2ALMNAHSD17B10CYP2C19 | |
| SCHEMBL4902901 | 0.79 | RAB9A (0.56) | ACERENITGB3ITGB1ITGAV | |
| SCHEMBL3103071 | 0.79 | ACE (0.60) | ACERENTHRBALOX12KMT2A | |
| SCHEMBL17285634 | 0.79 | ACE (0.46) | ACERENTHRBALOX12KMT2A | |
| SCHEMBL2422744 | 0.78 | ACE (0.48) | ACERENTHRBALOX12KMT2A | |
| SCHEMBL2422749 | 0.78 | ACE (0.48) | ACERENTHRBALOX12KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6852752-B2 | Urea compounds, compositions and methods of use and preparation | VICURON PHARMACEUTICALS INC. (US) | 2005-02-08 | — | — | US | disclosed |
| US-20020119962-A1 | Novel urea compounds, compositions and methods of use and preparation | VICURON HOLDINGS LLC | 2002-08-29 | — | — | US | disclosed |
| WO-2001044178-A1 | NOVEL UREA COMPOUNDS, COMPOSITIONS AND METHODS OF USE AND PREPARATION | VERSICOR, INC. (US) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119962-A1 | Novel urea compounds, compositions and methods of use and preparation | PDF, UROD, HDHD5 | ACE 1344/4885REN 1300/4885THRB 3677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.